Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RAVULIZUMAB-CWVZ: 10,229 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
10,229
Total FAERS Reports
551 (5.4%)
Deaths Reported
1,663
Hospitalizations
10,229
As Primary/Secondary Suspect
78
Life-Threatening
24
Disabilities
Prescription
Status

FDA Application: 761108 ·

First Report: 20080101 · Latest Report: 20250925

What Are the Most Common RAVULIZUMAB-CWVZ Side Effects?

#1 Most Reported
Fatigue
1,472 reports (14.4%)
#2 Most Reported
Asthenia
727 reports (7.1%)
#3 Most Reported
Headache
639 reports (6.2%)

All RAVULIZUMAB-CWVZ Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Fatigue 1,472 14.4% 2 127
Asthenia 727 7.1% 1 94
Headache 639 6.3% 3 73
Drug ineffective 570 5.6% 6 73
Off label use 451 4.4% 9 44
Muscular weakness 422 4.1% 2 38
Dyspnoea 414 4.1% 5 89
Malaise 353 3.5% 3 53
Haemoglobin decreased 346 3.4% 6 70
Myasthenia gravis 338 3.3% 8 139
Back pain 326 3.2% 1 35
Pain 318 3.1% 0 50
Therapeutic response shortened 316 3.1% 1 30
Death 313 3.1% 313 9
Feeling abnormal 307 3.0% 1 24
Diplopia 294 2.9% 0 17
Diarrhoea 279 2.7% 1 44
Nausea 278 2.7% 1 36
Arthralgia 251 2.5% 1 27
Haemolysis 242 2.4% 3 66

Who Reports RAVULIZUMAB-CWVZ Side Effects? Age & Gender Data

Gender: 53.8% female, 46.2% male. Average age: 55.5 years. Most reports from: US. View detailed demographics →

Is RAVULIZUMAB-CWVZ Getting Safer? Reports by Year

YearReportsDeathsHosp.
2008 1 0 0
2010 2 0 0
2013 3 0 2
2014 2 0 2
2015 5 0 1
2016 6 1 2
2017 4 0 1
2018 9 0 2
2019 277 9 50
2020 166 16 48
2021 134 14 52
2022 241 27 64
2023 638 39 168
2024 957 75 215
2025 490 81 186

View full timeline →

What Is RAVULIZUMAB-CWVZ Used For?

IndicationReports
Myasthenia gravis 3,781
Paroxysmal nocturnal haemoglobinuria 2,175
Product used for unknown indication 1,815
Atypical haemolytic uraemic syndrome 1,121
Neuromyelitis optica spectrum disorder 403
Off label use 259
Haemolytic uraemic syndrome 93
Thrombotic microangiopathy 62
C3 glomerulopathy 59
Renal transplant 11

RAVULIZUMAB-CWVZ vs Alternatives: Which Is Safer?

RAVULIZUMAB-CWVZ vs REBAMIPIDE RAVULIZUMAB-CWVZ vs REBETOL RAVULIZUMAB-CWVZ vs REBIF RAVULIZUMAB-CWVZ vs REBOXETINE RAVULIZUMAB-CWVZ vs RECLAST RAVULIZUMAB-CWVZ vs RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E RAVULIZUMAB-CWVZ vs REGADENOSON RAVULIZUMAB-CWVZ vs REGORAFENIB RAVULIZUMAB-CWVZ vs REGORAFENIB\REGORAFENIB RAVULIZUMAB-CWVZ vs RELATLIMAB

Official FDA Label for RAVULIZUMAB-CWVZ

Official prescribing information from the FDA-approved drug label.